Lydia joined NLC in April 2022 as a Venture Developer, focusing on innovations in Neuroscience and Neuroimmunology. She holds a BSc in Biology from Greece, an MSc in Pharmacology from the Netherlands and a PhD in Neuroscience from Sweden. She has 8+ years of R&D experience in academic and industrial settings (including Yale University and AstraZeneca) across 4 countries. Lydia has a strong interest in the business/commercial side of Life Sciences and is currently pursuing an MBA degree. She looks forward to applying her scientific knowledge in building ventures and ultimately helping NLC bring innovative science to patients in need.